2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 27.691 | 30.482 | 51.505 | 99.241 | 123.003 | 115.712 | 99.852 | 138.561 | 101.719 | 98.407 |
Total Income - EUR | 27.692 | 30.483 | 55.138 | 109.404 | 124.415 | 121.547 | 103.645 | 182.095 | 104.741 | 101.568 |
Total Expenses - EUR | 29.195 | 27.867 | 54.199 | 111.635 | 118.477 | 106.956 | 102.865 | 151.244 | 94.136 | 88.538 |
Gross Profit/Loss - EUR | -1.503 | 2.616 | 939 | -2.231 | 5.938 | 14.591 | 781 | 30.851 | 10.604 | 13.029 |
Net Profit/Loss - EUR | -2.334 | 1.702 | 418 | -3.293 | 4.708 | 13.416 | -146 | 29.481 | 9.732 | 12.146 |
Employees | 1 | 2 | 3 | 2 | 2 | 2 | 3 | 5 | 4 | 4 |
Check the financial reports for the company - Chatus Medvet Srl
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 1.969 | 1.986 | 10.736 | 16.123 | 32.995 | 37.301 | 38.208 | 81.219 | 83.466 | 85.187 |
Current Assets | 13.224 | 15.947 | 22.136 | 12.198 | 12.859 | 15.631 | 18.962 | 29.711 | 15.256 | 21.018 |
Inventories | 0 | 0 | 4.996 | 5.306 | 6.311 | 5.952 | 10.095 | 4.247 | 4.465 | 5.228 |
Receivables | 7.639 | 9.991 | 11.270 | 1.951 | 2.445 | 3.494 | 2.774 | 18.567 | 9.952 | 8.552 |
Cash | 5.585 | 5.956 | 5.870 | 4.941 | 4.103 | 6.185 | 6.093 | 6.896 | 839 | 7.238 |
Shareholders Funds | 7.985 | 9.754 | 10.072 | 6.609 | 9.627 | 22.856 | 22.442 | 51.425 | 52.061 | 61.624 |
Social Capital | 45 | 45 | 45 | 44 | 43 | 42 | 207 | 202 | 203 | 202 |
Debts | 7.208 | 8.179 | 22.801 | 21.721 | 36.227 | 30.077 | 34.729 | 59.506 | 46.660 | 44.581 |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "7500 - 7500" | |||||||||
CAEN Financial Year |
7500
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Chatus Medvet Srl